Skip to Content

Talectrectinib (Ibtrozi) for the Management of ROS1+ Advanced NSCLC

Download PQI pdf 0.24MB

Last Updated: July 7, 2025

By: Stefanie Houseknecht, PharmD, BCOP

About this PQI

The purpose of this document is to discuss the clinical considerations and general management of taletrectinib for the treatment of ROS1-positive Non-Small Cell Lung Cancer (NSCLC).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI